In an FDA reported letter Biogen and Elan issued concerns about the development of significant liver damage as a result of beginning Tysabri therapy.
Links to muliple sclerosis news stories
Feb
27
In an FDA reported letter Biogen and Elan issued concerns about the development of significant liver damage as a result of beginning Tysabri therapy.
Posted in news |